Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 24, 2015Eisai, CancerCare®, Cancer Support Community®, Cornucopia Cancer Support Center™ and Meals on Wheels America Continue their Commitment to Providing Meal Assistance to Enable Loved Ones to Spend More Quality Time Together
Magnolia Meals at Home®, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now helping those living with thyroid cancer. Sponsored...
- Sep 14, 2015
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for FYCOMPA® (perampanel) CIII Oral Suspension 0.5...
-
Aug 31, 2015Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered into a worldwide collaboration agreement for the development and...
- Aug 24, 2015Global Multicenter Study of FYCOMPA as Adjunctive Therapy Published in Neurology
Eisai Inc. announced today that the results of its Phase 3 trial (Study 332) for FYCOMPA® (perampanel) CIII have been published in the online edition of Neurology, the medical journal of the...
-
Jul 31, 2015Clinical trial will explore whether or not eribulin in combination with PEGPH20 can improve overall response rate in women with advanced breast cancer
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San Diego,...
